AT7519

ArtNr	HY-50940-5mg
Hersteller	MedChem Express
CAS-Nr.	844442-38-2
Menge	5 mg
Quantity options	100 mg 10mM/1mL 10 mg 50 mg 5 mg
Kategorie	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Colorectal Cancer Lymphatic System Cancer Bone Cancer
Typ	Inhibitors
Specific against	other
Purity	99.76
Formula	C16H17Cl2N5O2
Citations	Adv Sci (Weinh). 2024 Jan 6:e2305260. bioRxiv. 2024 September 07. Dev Biol. 2024 Jan 28:508:93-106. Exp Eye Res. 2023 Jan 22;227:109391. FASEB J. 2024 Apr 30;38(8):e23628. Glycobiology. 2022 Jun 16;cwac038. Harvard Medical School LINCS LIBRARY Oncogene. 2023 Oct 16. RNA Biol. 2021 Sep 30;1-8. Sci Rep. 2021 Mar 8;11(1):5374. Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. Cell Chem Biol. 2018 Feb 15;25(2):135-142.e5. Harvard Medical School LINCS LIBRARY [1]Santo L, et al. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene. 2010 Apr 22;29(16):2325-36. [2]Squires MS, et al. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. [3]Squires MS, et al. AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples. Mol Cancer Ther. 2010 Apr;9(4):920-8.
Smiles	O=C(NC1=CNN=C1C(NC2CCNCC2)=O)C3=C(Cl)C=CC=C3Cl
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	AT7519M
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Apoptosis; CDK
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	382.24448
Product Description	AT7519 (AT7519M) as a potent inhibitor of CDKs, with IC50s of 210, 47, 100, 13, 170, and <10 nM for CDK1, CDK2, CDK4 to CDK6, and CDK9, respectively.
Manufacturer - Research Area	Cancer
Solubility	DMSO : ≥ 50 mg/mL
Manufacturer - Pathway	Apoptosis; Cell Cycle/DNA Damage
Isoform	CDK1; CDK2; CDK4; CDK5; CDK6; CDK7; CDK9
Clinical information	Phase 2

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-50940-5mg-safety-datasheet.pdf